Harima B.Stem Corporation
First Quarter Financial Summary for the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)
For the first quarter of the fiscal year ending March 2027, consolidated net sales were JPY 8.27 billion, up 15.8% YoY. Operating profit was JPY 528 million, up 79.2% YoY; quarterly net income attributable to owners of the parent was JPY 370 million, up significantly. The full-year earnings guidance remains unchanged from the prior disclosure. The dividend forecast remains at 36 yen per share for the year (annual plan).
Key Figures
- Revenue: 82,07,000千円 (YoY +15.8%)
- Operating profit: 528,464千円 (YoY +81.1%)
- Net income attributable to owners of the parent: 370,396千円 (YoY +64.6%)
AI要約
Overview of performance
This quarter's net sales increased significantly year over year, driven by the full-scale operation of new properties, contract renewals, increased incidental work, and growth of group companies. On the profit front, cost of sales and selling, general and administrative expenses were restrained, resulting in substantial increases in operating income, ordinary income, and net profit. In line with the medium-term plan, investment in human resources and DX/AI investments was advanced to strengthen organizational capability and value addition.
Outlook and capital elements
Full-year earnings guidance remains unchanged since the previous disclosure. Even considering higher personnel costs and education/training expenses from the second quarter onward, the outlook remains in line with the initial plan. The financial position shows increases in cash and deposits and long-term borrowings, while liquidity, net assets, and overall positions remain sound.
Harima Biostem Co., Ltd.
Company overview · Stock price · Financial data · All IR
